Dako and Omnyx, LLC Launch Digital Pathology Solution for Breast Cancer Diagnostics
(Thomson Reuters ONE) -
GLOSTRUP, Denmark, Aug. 30, 2013 - Dako, an Agilent Technologies Company and
worldwide provider of cancer diagnostics, and Omnyx, LLC (a joint venture of GE
Healthcare and the University of Pittsburgh Medical Center) a leader in digital
pathology, announced today that they are launching clinical image analysis for
digital pathology in Europe.
By providing quantitative results for HercepTest, Dako and Omnyx enable a
confident diagnosis, with an overall aim of supporting pathologists in
generating accurate, objective and reproducible diagnostic results.
As part of the collaboration which began in 2010, Dako has used its expertise in
staining and image analysis to develop algorithms that are incorporated into the
Omnyx digital pathology platform as part of Omnyx's overall strategy of
providing pathologists with a comprehensive digital workflow. The HercepTest
image analysis tool is now accessible in the Omnyx system and has been
specifically customized for Dako's breast cancer prognostic markers.
"Omnyx envisions a future where image analysis and workflow empower pathologists
to make confident clinical decisions ultimately leading to better patient care,"
said Jim LaFrance, CEO of Omnyx. "Our partnership with Dako allows us to offer
image analysis to clinicians who use Dako tests. Image analysis for prognostic
markers within the Omnyx Integrated Digital Pathology workflow provides
pathologists with a powerful set of tools to improve both accuracy and
efficiency."
Digital pathology converts glass slides into digital images and efficiently
manages the resulting image data. It enables pathologists to improve
productivity by providing a virtual means of reviewing tissue sections without
handling traditional glass slides, and it offers digital image analysis tools to
help pathologists interpret tissue-based test results objectively. Digital
pathology holds tremendous potential for standardizing test interpretation and
enabling greater accuracy in cancer diagnostics.
"With this offering, Dako and Omnyx support pathologists in making confident,
efficient diagnoses based on both subjective and quantitative measures," said
Jakob Mohr Christensen, vice president of Global Marketing at Dako.
"Additionally, the algorithms link digital scanners to Dako reagents and
staining instruments, which give customers a complete and integrated solution.
Dako is committed to continually improving patient care by finding ways to
further enhance the standards and accuracy in cancer diagnostics."
CONTACTS
Dako Products:
Victoria Wadsworth-Hansen
Dako Denmark A/S
+45 29336980
Dako Corporate:
Maia Fredtoft Søchting
Dako Denmark A/S
+45 25461083
Omnyx, LLC:
Ryan Heath
GE HealthCare
+1 262 548 2407
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
About Omnyx
Omnyx, LLC is a joint venture of GE Healthcare and the University of Pittsburgh
Medical Center with locations in Pittsbugh, Pa., and Piscataway, N.J. The
company is developing an enterprise platform to transform the scope of pathology
to an all-digital workflow. The company will sell their digital pathology
platform to clinical labs and offer an enterprise software platform for image
management, workflow automation, image analysis algorithms and system
integration along with its high speed whole-slide scanners. Close collaboration
with pathologists at UPMC and other institutions along with their relationship
with GE Healthcare allows Omnyx to focus its innovation on the needs of anatomic
pathologists worldwide. Omnyx digital pathology products are currently in
development and have not yet been cleared by the U.S. Food and Drug
Administration. Information about Omnyx is available at www.omnyx.com.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees, operates in
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1726095]
Unternehmensinformation / Kurzprofil:
Datum: 30.08.2013 - 17:00 Uhr
Sprache: Deutsch
News-ID 292549
Anzahl Zeichen: 5626
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako and Omnyx, LLC Launch Digital Pathology Solution for Breast Cancer Diagnostics"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
